U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H21ClF2O4S
Molecular Weight 442.904
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0752

SMILES

OC(=O)CC[C@H]1CC[C@@](CC1)(C2=C(F)C=CC(F)=C2)S(=O)(=O)C3=CC=C(Cl)C=C3

InChI

InChIKey=XCGJIFAKUZNNOR-QCKZDCLWSA-N
InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)/t14-,21+

HIDE SMILES / InChI

Description

MK-0752 is a potent, reversible inhibitor of γ-secretase, which inhibits γ-secretase to cleave substrates such as amyloid precursor protein. MK-0752 shows promising effects on inhibiting the growth of several types of cancer cells and was investigated in clinical trials for cancer treatment. For example in ovarian cancer models MK-0752 alone actively induced cell growth inhibition, G2/M phase cell cycle arrest and apoptosis with down-regulation of Notch1 and its downstream effectors in a dose- and time-dependent manner. Moreover, the sequential combination of cisplatin prior to MK-0752 significantly promoted cell apoptosis and inhibited the subcutaneous xenograft growth of ovarian cancer in nude mice. Through its effects on the Notch pathway, MK-0752 reduces the number of breast cancer stem cells in tumorgrafts, enhancing the efficacy of the chemotherapy drug docetaxel in mice with breast cancer tumors. Unfortunately, in phase II clinical trials MK-0752 failed to demonstrate efficacy.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
Route of Administration: Oral